(MedPage Today) — The PCSK9 inhibitor evolocumab (Repatha) got the FDA’s blessing for cardiovascular protection, with or without a history of cardiovascular disease (CVD).
Evolocumab is now indicated for the wider pool of adults at increased…
Source link : https://www.medpagetoday.com/cardiology/dyslipidemia/117148
Author :
Publish date : 2025-08-25 20:36:00
Copyright for syndicated content belongs to the linked Source.
